Latest Regulatory Milestones News

Carbine Resources secures a pivotal mining lease for its Muchea West Silica Sand Project and raises $1.78 million to fuel exploration, marking significant progress in its Australian silica sand ventures.

Boab Metals has taken a major step forward in developing its Sorby Hills Lead-Silver-Zinc Project by acquiring the DeGrussa Processing Plant and completing a $6 million capital raise, positioning the company for a Final Investment Decision later this year.

Astron Corporation has cleared major regulatory hurdles for its Donald Rare Earth and Mineral Sands Project, releasing a robust updated economic study that underscores the project's long-term value and advancing financing discussions.

Venus Metals Corporation has made significant progress at its Bellchambers Gold Project with the granting of a mining lease and encouraging drilling results, while advancing base metals exploration at Youanmi.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

Bio-Gene Technology Limited has secured $2.45 million to fund critical safety studies and scale-up production of its novel insecticides Flavocide and Qcide, positioning the company for upcoming regulatory approvals and commercial partnerships.

Admiralty Resources has obtained temporary road transport approval in Chile, enabling the shipment of up to 150,000 tonnes of iron ore concentrate from its Mariposa project. This milestone advances the project closer to full production amid ongoing regulatory progress.

Environmental Clean Technologies Limited has secured crucial regulatory approvals for its Bacchus Marsh fertiliser facility and completed a $275K capital raise, while deferring field trials to better align with cropping cycles. The company is also undergoing significant restructuring to improve capital efficiency and focus on strategic growth.

Memphasys Limited has submitted its Felix™ sperm separation system for CE Mark approval, targeting Europe’s $5 billion IVF market, while expanding direct sales in Japan and validating its RoXsta™ oxidative stress diagnostic platform.

Diatreme Resources has achieved a significant milestone with its Northern Silica Project awarded Major Project Status and a 278% upgrade in its Si2 Deposit resource, positioning the company for long-term growth in the critical minerals sector.

Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.